Exploring the potential targets and mechanisms of artemisinin in the treatment of diabetic kidney disease using network pharmacology and molecular docking. Journal Abstract - Guideline Central

Exploring the potential targets and mechanisms of artemisinin in the treatment of diabetic kidney disease using network pharmacology and molecular docking.

Published: 2026 Jun 01

Authors

, ,

Abstract

Diabetic kidney disease (DKD) is a secondary glomerular disease caused by diabetes, and its incidence is increasing annually. Artemisinin is an organic compound with multiple pharmacological effects. This study aims to investigate the potential therapeutic effects of artemisinin on DKD and its molecular mechanisms. Common targets were identified using network pharmacology, transcriptome data from the Gene Expression Omnibus (GEO) database, and three machine learning algorithms, including Least Absolute Shrinkage and Selection Operator (LASSO), Support Vector Machine Recursive Feature Elimination (SVM-RFE), and Random Forest (RF). Target expression profiles were examined through single-cell sequencing data analysis. Molecular docking and cellular assays, including western blot, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), enzyme-linked immunosorbent assay (ELISA), and reactive oxygen species (ROS) detection, validated the effects of artemisinin and Fms related receptor tyrosine kinase 1(FLT1) on human renal glomerular endothelial cells (HRGECs) under a high-glucose (HG) injury model. A total of 64 common targets between artemisinin and DKD were identified, and machine learning identified FLT1 as a key target. Single-cell analysis revealed high FLT1 expression in DKD endothelial cells. More importantly, artemisinin exhibited stable binding to FLT1. HG reduced FLT1 expression and cell viability in HRGECs. Besides, HG-induced decrease in cell viability, increase in proportion of TUNEL-positive cells, elevation in the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and lipid ROS production were reversed by FLT1 overexpression or artemisinin treatment, and these protective effects of artemisinin were significantly attenuated upon FLT1 knockdown. Artemisinin alleviates HG-induced HRGEC injury by restoring FLT1 expression, providing a potential therapeutic target for DKD treatment.

Keywords: Artemisinin, Diabetic kidney disease, Fms related receptor tyrosine kinase 1, Machine learning, Molecular docking

Source

Functional & integrative genomics

Publication Type

Journal Article

Language

English

PubMed ID

42223693

MeSH terms

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.